search button

Aberrant expression of enhancer of zeste homologue 2, correlated with HIF-1α, refines relapse risk and predicts poor outcome for breast cancer

  • Authors:
    • Min Dong
    • Xin-Juan Fan
    • Zhan-Hong Chen
    • Tian-Tian Wang
    • Xing Li
    • Jie  Chen
    • Qu Lin
    • Jing-Yun Wen
    • Xiao-Kun Ma
    • Li Wei
    • Dan-Yun Ruan
    • Ze-Xiao Lin
    • Quentin Liu
    • Xiang-Yuan Wu
    • Xiang-Bo Wan

  • View Affiliations

  • Published online on: July 10, 2014     https://doi.org/10.3892/or.2014.3322
  • Pages: 1101-1107
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Overexpression of enhancer of zeste homologue 2 (EZH2), a key component of polycomb proteins, has been linked to aggressive tumor behavior in a variety of cancers. In vitro, hypoxia-inducible factor 1α (HIF-1α) transcriptionally activates EZH2 and promotes the progression of breast tumor initiating cells. Here, we characterized the clinicopathological effect of EZH2 and HIF-1α in 410 breast cancer patients. We examined EZH2 and HIF-1α expression using immunohistochemistry and western blotting. We found that EZH2 and HIF-1α were highly expressed in 99 (24.1%) and 272 (70.6%) patients, respectively. EZH2 overexpression was associated with lymphatic invasion (P=0.025), HER2 expression (P=0.005) and hypoxia (P<0.001). Overexpression of EZH2 predicted a poor 5-year overall survival (OS, 74.8 vs. 93.4%, P=0.001), disease-free survival (DFS, 72.2 vs. 88.6%, P=0.031), local failure-free survival (LFFS, 95.7 vs. 97.9%, P=0.045) and distant metastasis-free survival (DMFS, 75.4 vs. 90.5%, P=0.039). Multivariate analysis confirmed that EZH2 is an independent prognostic factor for OS, DFS and LFFS. Moreover, a positive correlation was identified between EZH2 and HIF-1α (r=0.299, P<0.001). Importantly, tumors coexpressing HIF-1α and EZH2 had a poorer OS (P=0.007). In conclusion, our study demonstrated that EZH2 is an independent negative prognostic biomarker for breast cancer. Tumors overexpressing HIF-1α and EZH2 are more prone to disease progression.
View Figures
View References

Related Articles

Journal Cover

September-2014
Volume 32 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 4.2
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 8.4
  • CiteScore Rank: Q1: #68/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.786
  • SCImago Journal Rank (SJR): 0.812
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Dong M, Fan X, Chen Z, Wang T, Li X, Chen J, Lin Q, Wen J, Ma X, Wei L, Wei L, et al: Aberrant expression of enhancer of zeste homologue 2, correlated with HIF-1α, refines relapse risk and predicts poor outcome for breast cancer. Oncol Rep 32: 1101-1107, 2014
APA
Dong, M., Fan, X., Chen, Z., Wang, T., Li, X., Chen, J. ... Wan, X. (2014). Aberrant expression of enhancer of zeste homologue 2, correlated with HIF-1α, refines relapse risk and predicts poor outcome for breast cancer. Oncology Reports, 32, 1101-1107. https://doi.org/10.3892/or.2014.3322
MLA
Dong, M., Fan, X., Chen, Z., Wang, T., Li, X., Chen, J., Lin, Q., Wen, J., Ma, X., Wei, L., Ruan, D., Lin, Z., Liu, Q., Wu, X., Wan, X."Aberrant expression of enhancer of zeste homologue 2, correlated with HIF-1α, refines relapse risk and predicts poor outcome for breast cancer". Oncology Reports 32.3 (2014): 1101-1107.
Chicago
Dong, M., Fan, X., Chen, Z., Wang, T., Li, X., Chen, J., Lin, Q., Wen, J., Ma, X., Wei, L., Ruan, D., Lin, Z., Liu, Q., Wu, X., Wan, X."Aberrant expression of enhancer of zeste homologue 2, correlated with HIF-1α, refines relapse risk and predicts poor outcome for breast cancer". Oncology Reports 32, no. 3 (2014): 1101-1107. https://doi.org/10.3892/or.2014.3322